Literature DB >> 24249742

Bruton's tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system.

Gabriela López-Herrera1, Alexander Vargas-Hernández, Maria Edith González-Serrano, Laura Berrón-Ruiz, Juan Carlos Rodríguez-Alba, Francisco Espinosa-Rosales, Leopoldo Santos-Argumedo.   

Abstract

Btk is the protein affected in XLA, a disease identified as a B cell differentiation defect. Btk is crucial for B cell differentiation and activation, but its role in other cells is not fully understood. This review focuses on the function of Btk in monocytes, neutrophils, and platelets and the receptors and signaling cascades in such cells with which Btk is associated.

Entities:  

Keywords:  TLRs; XLA; inflammation

Mesh:

Substances:

Year:  2013        PMID: 24249742     DOI: 10.1189/jlb.0513307

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  36 in total

1.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Authors:  Patrick F Smith; Janakan Krishnarajah; Philip A Nunn; Ron J Hill; Dane Karr; D Tam; Mohammad Masjedizadeh; Jens O Funk; Steve G Gourlay
Journal:  Br J Clin Pharmacol       Date:  2017-08-01       Impact factor: 4.335

2.  Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.

Authors:  Jon M Florence; Agnieszka Krupa; Laela M Booshehri; Sandra A Davis; Michael A Matthay; Anna K Kurdowska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-08       Impact factor: 5.464

3.  Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.

Authors:  Wei Kong; Wei Deng; Yue Sun; Saisai Huang; Zhuoya Zhang; Bingyu Shi; Weiwei Chen; Xiaojun Tang; Genhong Yao; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

4.  IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.

Authors:  Sunita Keshari; Chien-Lung Chen; Apriska Dewi Sipayung; Ching-Chuan Hsieh; Li-Jen Su; Yun-Ru Chiang; Huan-Cheng Chang; Wu-Chang Yang; Tsung-Hsien Chuang; Chun-Ming Huang
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

Review 5.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

6.  Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Authors:  Philipp Haselmayer; Montserrat Camps; Lesley Liu-Bujalski; Ngan Nguyen; Federica Morandi; Jared Head; Alison O'Mahony; Simone C Zimmerli; Lisa Bruns; Andrew T Bender; Patricia Schroeder; Roland Grenningloh
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

7.  Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.

Authors:  Rachel A Rigg; Joseph E Aslan; Laura D Healy; Michael Wallisch; Marisa L D Thierheimer; Cassandra P Loren; Jiaqing Pang; Monica T Hinds; András Gruber; Owen J T McCarty
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-09       Impact factor: 4.249

8.  Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.

Authors:  Nicole Grabinski; Florian Ewald
Journal:  Invest New Drugs       Date:  2014-08-01       Impact factor: 3.850

9.  High-throughput sequencing reveals an altered T cell repertoire in X-linked agammaglobulinemia.

Authors:  Manish Ramesh; Noa Simchoni; David Hamm; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2015-09-07       Impact factor: 3.969

10.  BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.

Authors:  Samantha A Chalmers; Elizabeth Glynn; Sayra J Garcia; Mark Panzenbeck; Josephine Pelletier; Janice Dimock; Elise Seccareccia; Todd Bosanac; Sara Khalil; Christian Harcken; Deborah Webb; Gerald Nabozny; Jay S Fine; Donald Souza; Elliott Klein; Leal Herlitz; Meera Ramanujam; Chaim Putterman
Journal:  Clin Immunol       Date:  2018-10-16       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.